FDA urged to withdraw DNA test predicting opioid addiction, AvertD

In the United States, the opioid epidemic continues to claim the lives of over 130 people daily, resulting in roughly 110,000 deaths annually. The FDA has taken steps to address this crisis, such as approving the over-the-counter sale of naloxone nasal spray and a DNA test called AvertD to predict genetic risk of opioid addiction. However, there are concerns about the scientific validity of the AvertD test, with experts urging the FDA to remove it from the market and advising against Medicaid and Medicare funding for a test they deem ineffective. The battle against opioid addiction and related deaths remains a pressing public health issue.

Source link

error: Content is protected !!